EXD-12

EXD-12 is an investigational **live attenuated herpes simplex virus vaccine** being developed by Excell Biotech for both prevention and treatment of herpes simplex virus infection. The candidate is described as targeting **HSV-1 and HSV-2**, positioning it as both a prophylactic and therapeutic vaccine. Publicly available context indicates that EXD-12 was in **preclinical** evaluation for safety and efficacy in the United States, and a provisional US patent application was filed in September 2018. Its proposed activity is to induce antiviral immune responses against herpes simplex virus through administration of a weakened live viral vaccine construct, although specific engineered viral features, antigen design details, and administration parameters have not been publicly disclosed in the provided materials.